Paul Kim

Mr. Paul Kim

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
DCDongwon Choi
Dongwon Choi
EPEunkyung Park
Eunkyung Park
EJEunson Jung
Eunson Jung
BCBoksik Cha
Boksik Cha
SLSomin Lee
Somin Lee
YHYoung-Kwon Hong
Young-Kwon Hong
The lymphatic system plays crucial roles in tissue homeostasis, lipid absorption, and immune cell trafficking. Although lymphatic valves ensure unidirectional lymph flows, the flow itself controls lymphatic valve formation. Here, we demonstrate that a mechanically activated ion channel Piezo1 senses oscillating shear stress (OSS) and incorporates the signal into the genetic program controlling lymphatic valve development and maintenance. Time-controlled deletion of Piezo1 using a pan-endothelial Cre driver ( Cdh5[PAC]-CreER T2 ) or lymphatic-specific Cre driver ( Prox1-CreER T2 ) equally inhibited lymphatic valve formation in newborn mice. Furthermore, Piezo1 deletion in adult lymphatics caused substantial lymphatic valve degeneration. Piezo1 knockdown in cultured lymphatic endothelial cells (LECs) largely abrogated the OSS-induced upregulation of the lymphatic valve signature genes. Conversely, ectopic Piezo1 overexpression upregulated the lymphatic valve genes in the absence of OSS. Remarkably, activation of Piezo1 using chemical agonist Yoda1 not only accelerated lymphatic valve formation in animals, but also triggered upregulation of some lymphatic valve genes in cultured LECs without exposure to OSS. In summary, our studies together demonstrate that Piezo1 is the force sensor in the mechanotransduction pathway controlling lymphatic valve development and maintenance, and Piezo1 activation is a potentially novel therapeutic strategy for congenital and surgery-associated lymphedema.

26 May 2020 in Journal of Eukaryotic Microbiology
Verified
Journal Article
Closed access
PDF file
WKWilliam E. Kumler
William E. Kumler
JJJustin Jorge
Justin Jorge
PKPaul Kim
Paul Kim
NINoama Iftekhar
Noama Iftekhar
MKM. A. R. Koehl
M. A. R. Koehl

30 September 2018 in International Neurourology Journal
Verified
Journal Article
Open access
PDF file
RPRebekah J. Park
Rebekah J. Park
YHYeo Jin Hong
Yeo Jin Hong
YWYifan Wu
Yifan Wu
PKPaul Kim
Paul Kim
YHYoung-Kwon Hong
Young-Kwon Hong

1 July 2018 in Tuberculosis
Verified
Journal Article
Closed access
PKPaul Kim
Paul Kim
JLJae-Jin Lee
Jae-Jin Lee
DCDongwon Choi
Dongwon Choi
HEHyungjin Eoh
Hyungjin Eoh
YHYoung-Kwon Hong
Young-Kwon Hong

1 June 2023 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
SASajjad Ali
Sajjad Ali
PKPaul Kim
Paul Kim
SDSorabh Dhar
Sorabh Dhar

25 April 2023 in COVID
Verified
Journal Article
Open access
PDF file
PKPaul Kim
Paul Kim
VNVidhya Nadarajan
Vidhya Nadarajan
MAMaham Ahmed
Maham Ahmed
KFKaterina Furman
Katerina Furman
ZGZoya Gurm
Zoya Gurm
DKDragana Komnenov
Dragana Komnenov
(1) Background: Data on COVID-19 outcomes and disease course as a function of different medications used to treat cardiovascular disease and chronic kidney disease (CKD), as well as the presence of different comorbidities in primarily Black cohorts, are lacking. (2) Methods: We conducted a retrospective medical chart review on 327 patients (62.6% Black race) who were admitted to the Detroit Medical Center, Detroit, MI. Group differences (CKD vs. non-CKD) were compared using the Pearson χ2 test. We conducted univariate and multivariate regression analyses for factors contributing to death during hospitalization due to COVID-19 (primary outcome) and ICU admission (secondary outcome), adjusting for age, sex, different medications, and comorbidities. A sub-analysis was also completed for CKD patients. (3) Results: In the fully adjusted model, a protective effect of ACEi alone, but not in combination with ARB or CCB, for ICU admission was found (OR = 0.400, 95% CI [0.183–0.874]). Heart failure was significantly associated with the primary outcome (OR = 4.088, 95% CI [1.1661–14.387]), as was COPD (OR = 3.747, 95% CI [1.591–8.828]). (4) Conclusions: Therapeutic strategies for cardiovascular disease and CKD in the milieu of different comorbidities may need to be tailored more prudently for individuals with COVID-19, especially Black individuals.